Evidence map›Paper›PMID 39420932›Full record

Trial reportArchives of endocrinology and metabolism2024

GDF-15 levels in patients with polycystic ovary syndrome treated with metformin: a combined clinical and in silico pathway analysis.

Fernanda M V Magalhães, Rodrigo M C Pestana, Cláudia N Ferreira, Ieda F O Silva, Ana L Candido, Flávia R Oliveira, Fernando M Reis, Karina B Gomes

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Archives of endocrinology and metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Fernanda M V MagalhãesFaculdade de Farmácia Universidade Federal de Minas Gerais Belo HorizonteMG Brasil Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil.ORCID https://orcid.org/0009-0009-9055-6523
Rodrigo M C PestanaFaculdade de Medicina Universidade Federal de Minas Gerais Belo HorizonteMG Brasil Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil.ORCID https://orcid.org/0000-0003-2713-9726
Cláudia N FerreiraColégio Técnico Universidade Federal de Minas Gerais Belo HorizonteMG Brasil Colégio Técnico, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil.ORCID https://orcid.org/0000-0003-4545-6821
Ieda F O SilvaFaculdade de Farmácia Universidade Federal de Minas Gerais Belo HorizonteMG Brasil Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil.ORCID https://orcid.org/0000-0002-1843-2632
Ana L CandidoFaculdade de Medicina Universidade Federal de Minas Gerais Belo HorizonteMG Brasil Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil.ORCID https://orcid.org/0000-0002-9080-2319
Flávia R OliveiraFaculdade de Medicina Universidade Federal de Minas Gerais Belo HorizonteMG Brasil Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil.ORCID https://orcid.org/0000-0001-6282-7781
Fernando M ReisFaculdade de Medicina Universidade Federal de Minas Gerais Belo HorizonteMG Brasil Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil.ORCID https://orcid.org/0000-0002-9258-7472
Karina B GomesFaculdade de Farmácia Universidade Federal de Minas Gerais Belo HorizonteMG Brasil Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil.ORCID https://orcid.org/0000-0002-6870-2063

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Polycystic ovary syndrome (PCOS) is an endocrine disease characterized by metabolic, reproductive, and psychological manifestations. Growth and differentiation factor 15 (GDF-15) is a cytokine associated with metabolic and inflammatory disorders. Metformin is commonly used for the treatment of PCOS. We investigated the relationship between GDF-15 levels and PCOS, the effect of metformin on GDF-15 levels, and potential biologic pathways related to GDF-15. Subjects and methods: The study included 35 women with PCOS and 32 women without PCOS (controls). Both groups were compared in terms of GDF-15 levels. Additional analysis was conducted on samples from 22 women with PCOS who were treated with either metformin (n = 7) or placebo (n = 15), retrieved from a previous randomized, controlled trial. Levels of GDF-15 were measured using MILLIPLEX. The biologic pathways related to GDF-15 were evaluated using the databases STRING, SIGNOR, and Pathway Commons. The statistical analysis was conducted using the software SPSS. Results: Levels of GDF-15 were higher in the PCOS group compared with the non-PCOS group (p = 0.039). Among women with PCOS, GDF-15 levels were higher in those treated with metformin compared with placebo (p = 0.007). The proteins related to GDF-15 overlapped between the databases, and a significant interaction was found between GDF-15 and proteins related to PCOS and its complications, including those related to estrogen response, oxidative stress, ovarian infertility, interleukin (IL)-18, IL-4, the ratio of advanced glycation end products to their receptor (AGE/RAGE), leptin, transforming growth factor beta (TGF-β), adipogenesis, and insulin. Conclusion: The findings of the present study suggest a relationship between GDF-15 and PCOS and a potential increase in GDF-15 levels with metformin treatment. An additional finding was that GDF-15 could be involved in biologic pathways related to PCOS complications.

Indexed as

Growth Differentiation Factor 15Hypoglycemic AgentsMetforminPolycystic Ovary SyndromeAdultBiomarkersCase-Control StudiesFemaleHumansYoung AdultBiomarkersGDF15 protein, humanGrowth Differentiation Factor 15Hypoglycemic AgentsMetforminbiologic pathwaysGDF-15metforminpolycystic ovary syndrome

Identifiers

PMID39420932
PMCPMC11460967

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.